MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases

Last updated: February 21, 2025
Sponsor: Centre Hospitalier Universitaire de Nice
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mitochondrial Diseases

Treatment

diagnosis of mitochondrial myopathy

Clinical Study ID

NCT04920812
19-API-01
2020-A02651-38
  • All Genders

Study Summary

MITOMICS aims to determine which RNA-Seq results (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. Analysis of RNA-Seq and WES results will performed with a computational approach using an autoencoder-based method

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients suspected of a mitochondrial disease with muscular signs (clinical,histological or biochemical)

  • Patients with negative mtDNA and WES NGS in trio

  • Patients with routine muscle and skin biopsies available

  • Blood samples from parents and / or relatives available for segregation studies

  • Informed consent of the study signed by the patient or the legal representatives ofthe minor patient or under guardianship

  • Patients affiliated to social security

Exclusion

Exclusion Criteria:

  • Patients with suspected mitochondrial disease without muscle involvement

  • Patients for whom the mtDNA NGS and WES have not been performed

  • Patients with suspected mitochondrial disease with causal variant identified

  • Refusal to sign the informed consent for the study

  • Insufficient amount of frozen material or culture failure for fibroblasts

Study Design

Total Participants: 66
Treatment Group(s): 1
Primary Treatment: diagnosis of mitochondrial myopathy
Phase:
Study Start date:
March 07, 2022
Estimated Completion Date:
September 07, 2025

Study Description

Mitochondrial diseases (MD) are rare, clinically and genetically extremely heterogeneous, caused by a deficit of energy production via the mitochondria. Mitochondria are dependent on 2 genomes mitochondrial DNA and nuclear DNA, and many pathogenic variants carried by these 2 genomes are responsible for mitochondrial diseases. The diagnostic strategies for MD patients have evolved significantly with the emergence of Next Generation Sequencing (NGS) also accelerating the identification of the responsible gene. However, the diagnostic yield remains limited and requires the development of new approaches. Previous studies showed that WES and RNA-Seq combination improves the diagnosis of MD, essentially by helping in the interpretation of identified VUS.

With MITOMICS project, we will included 66 patients suspected of a mitochondrial myopathy (clinical, histological or biochemical), with a negative mtDNA and WES NGS in trio. For each patient we will sequenced RNA from muscle and fibroblasts. Using a new innovative methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy. The results obtained will allow the interpretation of VUS and the identification of specific molecular signatures.

Connect with a study center

  • CHU de Nice

    Nice, Chu de Nice 06003
    France

    Active - Recruiting

  • chu Angers

    Angers,
    France

    Active - Recruiting

  • C.H.R.U. Brest

    Brest,
    France

    Site Not Available

  • Chu Brest

    Brest,
    France

    Site Not Available

  • APHM

    Marseille,
    France

    Active - Recruiting

  • Chu Montpellier

    Montpellier,
    France

    Active - Recruiting

  • CHU Nantes

    Nantes,
    France

    Site Not Available

  • Chu de Nantes

    Nantes,
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.